Lipocomb (Ezetimibe, Rosuvastatin Zinc)

• Lipocomb is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways.
• Primary hypercholesterolemia: reduces LDL‑C to recommended therapeutic targets.
• Mixed dyslipidemia: improves the overall lipid profile, lowering triglycerides and raising HDL‑C.
• Familial hypercholesterolemia: provides additional LDL‑C reduction when statin monotherapy is insufficient.

• Ezetimibe inhibits the Niemann‑Pick C1‑like 1 (NPC1L1) transporter in the intestinal brush border, blocking dietary and biliary cholesterol absorption. Rosuvastatin, a high‑potency HMG‑CoA reductase inhibitor, decreases hepatic cholesterol synthesis, leading to up‑regulation of LDL receptors and enhanced clearance of circulating LDL‑C.

Lipocomb may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Myalgia: muscle aches without weakness.
• Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea.
• Elevated liver enzymes: mild transaminase rise.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with dark urine.
• Hepatotoxicity: significant liver injury indicated by marked enzyme elevation.
• Acute renal failure: sudden loss of kidney function.
• Severe hypersensitivity: rash, angioedema or anaphylaxis.
• Thrombocytopenia: low platelet count.
• Myocardial infarction: rare but reported in high‑risk patients.

• Before initiating Lipocomb, consider the following safety measures.
• Liver function monitoring: obtain baseline transaminases and repeat periodically.
• Renal impairment: adjust therapy in patients with severe kidney disease.
• Drug‑induced myopathy: assess risk when combined with other statins or fibrates.
• Pregnancy and lactation: avoid use unless clearly indicated by a physician.
• Alcohol consumption: limit intake as it may increase liver toxicity.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Lipocomb can interact with several medication classes; awareness of the interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase rosuvastatin exposure.
• Cyclosporine: markedly raises rosuvastatin plasma levels, raising myopathy risk.
• Gemfibrozil: synergistic increase in statin‑related muscle toxicity.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce ezetimibe absorption.
• Warfarin: potential alteration of INR, requiring closer monitoring.
• Niacin: may increase risk of hepatotoxicity.
• Digoxin: slight increase in serum concentrations.
• Antihypertensives: monitor blood pressure as lipid‑lowering therapy can affect vascular tone.